Clinically, 89Zr-immuno-PET has demonstrated significant utility in oncology, particularly for imaging tumours overexpressing human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) [11], and vascular endothelial growth factor (VEGF) [12,13]. Here, ERBB2 is linked to neoplasm.